Beta blockers in the management of chronic kidney disease

Kidney International

Volumn 70, Issue 11, 2006, Pages 1905-1913

  Bakris, G L ^a   Hart, P ^b   Ritz, E ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b Jr Hospital of Cook County   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Beta blockers; Kidney disease; Renal function

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ANTIOXIDANT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CATECHOLAMINE; DOXORUBICIN; FREE RADICAL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LABETALOL; METOPROLOL; MINERALOCORTICOID ANTAGONIST; NORADRENALIN; OXYGEN RADICAL; POTASSIUM; PROPRANOLOL; RENIN; SODIUM; TRIACYLGLYCEROL; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

ADRENERGIC SYSTEM; ALBUMINURIA; ALPHA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; DIALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART FAILURE; HEART OUTPUT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; RENIN RELEASE; REVIEW; SYMPATHETIC TONE; SYSTEMIC CIRCULATION; VASOCONSTRICTION; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 33845267499     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001835     Document Type: Review

References (122)

1. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension 2003; 41: 621-624.
2. Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 2002; 4: 256-260.
3. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-727.
4. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-882.
5. Ye S, Zhong H, Yanamadala V et al. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15: 717-724.
6. Salplachta J, Bartosikova L, Necas J. Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys 2002; 21: 189-195.
7. Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996; 11: 1003-1011.
8. Strojek K, Grzeszczak W, Gorska J et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001; 12: 602-605.
9. Vonend O, Marsalek P, Russ H et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-1717.
10. Jovanovic D, Jovovic D, Mihailovic-Stanojevic N et al. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 2005; 63: 446-453.
11. Amann K, Ritz E. Microvascular disease - the Cinderella of uraemic heart disease. Nephrol Dial Transplant 2000; 15: 1493-1503.
12. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
13. Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-1478.
14. Zuanetti G, Maggioni AP, Keane W et al. Nephrologists neglect administration of betablockers to dialysed diabetic patients. Nephrol Dial Transplant 1997; 12: 2497-2500.
15. Paoletti E, Specchia C, Di Maio G et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19: 1829-1834.
16. Mann JF, Jakobs KH, Riedel J et al. Reduced chronotropic responsiveness of the heart in experimental uremia. Am J Physiol 1986; 250: H846-H852.
17. Leineweber K, Heinroth-Hoffmann I, Ponicke K et al. Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol 2002; 13: 117-124.
18. Rascher W, Schomig A, Kreye VA et al. Diminished vascular response to noradrenaline in experimental chronic uremia. Kidney Int 1982; 21: 20-27.
19. Converse Jr RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918.
20. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328.
21. Klein IH, Ligtenberg G, Oey PL et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-2433.
22. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979.
23. Eknoyan G. On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes. Am J Kidney Dis 1998; 32: S1-S4.
24. Abbott KC, Trespalacios FC, Agodoa LY et al. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004; 164: 2465-2471.
25. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
26. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
27. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int 2002; 62: 1784-1790.
28. Horl MP, Horl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17: 288-294.
29. Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens 2003; 16: 7S-12S.
30. Trespalacios FC, Taylor AJ, Agodoa LY et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002; 62: 1799-1805.
31. Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137: 563-570.
32. Richards DA, Prichard BN. Clinical pharmacology of labetalol. Br J Clin Pharmacol 1979; 8: 89S-93S.
33. Inderal® (propranolol hydrochloride) tablets (prescribing information). Wyeth Pharmaceuticals Inc.: Philadelphia, PA, 2005.
34. Tenormin® (atenolol) tablets (prescribing information). AstraZeneca Pharmaceuticals: Wilmington, DE, 2000.
35. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000; 95(Suppl 1): I41-I45.
36. Cruz F, O'Neill Jr WM, Clifton G et al. Effects of labetalol and methyldopa on renal function. Clin Pharmacol Ther 1981; 30: 57-63.
37. Epstein M, Oster JR, Hollenberg NK. β-Blockers and the kidney: implications for renal function and renin release. The Physiologist 1985; 28: 53-63.
38. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955-959.
39. Jacob S, Rett K, Wicklmayr M et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14: 489-494.
40. Hylander B, Eliasson K, Nilsson-Ehle P et al. Effects of long-term therapy with labetalol on lipoprotein metabolism in patients with mild hypertension. Acta Med Scand 1985; 218: 51-54.
41. Malini PL, Strocchi E, Negroni S et al. Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol 1982; 13: 123S-126S.
42. Drug Facts and Comparisons 2006. Facts and Comparisons (a Wolters Kluwer Company): St Louis, MO, 2005.
43. Meier J. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am Heart J 1982; 104: 364-373.
44. Borchard U. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem 1990; 8(Suppl 2): 28-34.
45. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998; 41: 39-52.
46. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258-1265.
47. Williams ME, Gervino EV, Rosa RM et al. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med 1985; 312: 823-827.
48. Arrizabalaga P, Montoliu J, Martinez VA et al. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc 1983; 20: 572-576.
49. Mehrotra S, Ling KL, Bekele Y et al. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus. Diabet Med 2001; 18: 109-115.
50. Onozato ML, Tojo A, Goto A et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61: 186-194.
51. Ueno Y, Kizaki M, Nakagiri R et al. Dietary glutathione protects rats from diabetic nephropathy and neuropathy. J Nutr 2002; 132: 897-900.
52. Dupont AG. Carvedilol and the kidney. Clin Investig 1992; 70(Suppl 1): S127-S131.
53. Salomonsson M, Brannstrom K, Arendshorst WJ. Alpha(1)-adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies. Am J Physiol Renal Physiol 2000; 278: F138-F147.
54. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359.
55. Epstein M, Oster JR. Beta blockers and renal function: a reappraisal. J Clin Hypertens 1985; 1: 85-99.
56. Abbott KC, Bakris G. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol 1993; 33: 392-399.
57. Zech P, Pozet N, Labeeuw M et al. Acute renal effects of beta-blockers. Am J Nephrol 1986; 6(Suppl 2): 15-19.
58. UKPD Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.
59. Parving HH, Andersen AR, Smidt UM et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ (Clin Res Ed) 1987; 294: 1443-1447.
60. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661.
61. Sugino G, Barg AP, O'Connor DT. Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension. Am J Kidney Dis 1984; 3: 357-361.
62. Dreslinski GR, Messerli FH, Dunn FG et al. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension. Circulation 1982; 65: 1365-1368.
63. Van den Meiracker AH, Mani V, Boomsma F et al. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 1989; 80: 903-914.
64. Wilkinson R, Stevens IM, Pickering M et al. A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension. Br J Clin Pharmacol 1980; 10: 51-59.
65. Ljungman S, Wikstrand J, Hartford M et al. Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension. Am J Hypertens 1993; 6: 554-563.
66. Yasumoto R, Asakawa M, Kakinoki K et al. Effect of metoprolol in patients with renal hypertension. Hinyokika Kiyo 1988; 34: 1669-1673.
67. Tindall H, Urquhart S, Stickland M et al. Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. Curr Med Res Opin 1991; 12: 516-520.
68. Cook ME, Wallin JD, Clifton GG et al. Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity. Clin Pharmacol Ther 1988; 43: 393-399.
69. Seiler KU, Schuster KJ, Meyer GJ et al. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet 1980; 5: 192-198.
70. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999; 55: 1528-1535.
71. Branten AJ, Hilbrands LB, van Hamersvelt HW et al. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrol Dial Transplant 1998; 13: 423-426.
72. Kirch W, Kohler H, Mutschler E et al. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 1981; 19: 65-71.
73. Jordo L, Attman PO, Aurell M et al. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet 1980; 5: 169-180.
74. Suwelack B, Kobelt V, Erfmann M et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003; 16: 313-320.
75. Hara Y, Hamada M, Shigematsu Y et al. Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients. Clin Sci (London) 2001; 101: 219-225.
76. Bjorck S, Mulec H, Johnsen SA et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-343.
77. Hannedouche T, Landais P, Goldfarb B et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833-837.
78. Lacourciere Y, Nadeau A, Poirier L et al. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993; 21: 786-794.
79. Apperloo AJ, de Zeeuw D, Sluiter HE et al. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 1991; 303: 821-824.
80. Himmelmann A, Hansson L, Hansson BG et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 1995; 4: 85-90.
81. Wright JT, Bakris G, Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002; 288: 2421-2431.
82. Bauer JH, Brooks CS. The long-term effect of propranolol therapy on renal function. Am J Med 1979; 66: 405-410.
83. van Zwieten PA. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs 1993; 45: 509-517.
84. Wallin JD. Adrenoreceptors and renal function. J Clin Hypertens 1985; 1: 171-178.
85. Keusch G, Weidmann P, Ziegler WH et al. Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. Klin Wochenschr 1980; 58: 25-29.
86. Rasmussen S, Nielsen PE. Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension. Br J Clin Pharmacol 1981; 12: 349-353.
87. Barbieri C, Ferrari C, Caldara R et al. Endocrine and metabolic effects of labetalol in man. J Cardiovasc Pharmacol 1981; 3: 986-991.
88. Ohman KP, Weiner L, von Schenck H et al. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. Eur J Clin Pharmacol 1985; 29: 149-154.
89. Andersson O, Berglund G, Hansson L. Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol. Br J Clin Pharmacol 1976; 3: 757-761.
90. Sommers DK, de Villiers LS, van Wyk M et al. The effects of labetalol and oxprenolol on blood lipids. S Afr Med J 1981; 60: 379-380.
91. Frishman WH. Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia. Cardiovasc Drugs Ther 1988; 2: 343-353.
92. Halstenson CE, Opsahl JA, Pence TV et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther 1986; 40: 462-468.
93. McCauley J, Murray J, Jordan M et al. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol 2002; 22: 347-351.
94. Hamad A, Salameh M, Zihlif M et al. Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol 2001; 21: 241-244.
95. Yoshikawa T, Port JD, Asano K et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996; 17(Suppl B): 8-16.
96. Dupont AG, Van der NP, Taeymans Y et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10(Suppl 11): S130-S136.
97. Calo LA, Semplicini A, Davis PA. Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients. Am J Med 2005; 118: 201-202.
98. Tomita K, Makumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992; 19(Suppl 1): S97-S101.
99. Kohno M, Takeda T, Ishii M et al. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan. Drugs 1988; 36(Suppl 6): 129-135.
100. Takeda T, Kohno M, Ishii M et al. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. Eur J Clin Pharmacol 1990; 38(Suppl 2): S158-S163.
101. Gehr TW, Tenero DM, Boyle DA et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999; 55: 269-277.
102. Miki S, Masumura H, Kaifu Y et al. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. J Cardiovasc Pharmacol 1991; 18(Suppl 4): S62-S68.
103. Masumura H, Miki S, Kaifu Y et al. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. J Cardiovasc Pharmacol 1992; 19(Suppl 1): S102-S107.
104. Deetjen A, Heidland A, Pangerl A et al. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients. Clin Nephrol 1995; 43: 47-52.
105. Nowicki M, Szewczyk-Seifert G, Klimek D et al. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 2002; 57: 352-358.
106. Leeman M, Vereerstraeten P, Uytdenhoef M et al. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients. J Cardiovasc Pharmacol 1993; 22: 706-710.
107. Kaijser M, Johnsson C, Zezina L et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant 1997; 11: 577-581.
108. Calo L, Giacon B, Davis PA et al. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clin Nephrol 2002; 58: 103-110.
109. Rahman M, Smith MC. Chronic renal insufficiency: a diagnostic and therapeutic approach. Arch Intern Med 1998; 158: 1743-1752.
110. Abraham WT, Tsvetkova T, Lowes BD et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation 1998; 98: I-378-I-379.
111. Komajda M, Lutiger B, Madeira H et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (carvedilol ACE-inhibitor remodelling mild CHF evaluation). Eur J Heart Fail 2004; 6: 467-475.
112. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890.
113. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12: 212-221.
114. Agrawal B, Wolf K, Berger A et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996; 10: 551-555.
115. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract 1999; 53: 519-522.
116. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236.
117. Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46: 1309-1315.
118. Giner V, Tormos C, Chaves FJ et al. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004; 255: 588-594.
119. Raats CJ, Bakker MA, van den BJ et al. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272: 26734-26741.
120. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633-651.
121. Kakoki M, Hirata Y, Hayakawa H et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999; 33(Part 2): 467-471.
122. Greven J, Gabriels G. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function. Arzneimittelforschung 2000; 50: 973-979.